Skip to main content

In vitro studies in the development of monoclonal antibodies (mAbs)

In vitro studies are essential in the development of monoclonal antibodies (mAbs) like nivolumab, a checkpoint inhibitor targeting the PD-1 (programmed cell death protein-1) receptor. These studies aim to elucidate various pharmacological and biophysical properties before moving into animal and human studies. Here’s how in vitro studies are applied in the development of nivolumab and similar mAbs:

1. Target Binding and Affinity Assessment

  • Binding Assays: Surface plasmon resonance (SPR) and enzyme-linked immunosorbent assays (ELISA) are common techniques used to determine the binding kinetics of nivolumab to PD-1. These studies establish the binding affinity (Kd), association, and dissociation rates of nivolumab to its target.
  • Epitope Mapping: Epitope mapping identifies the specific PD-1 region that nivolumab binds. It’s crucial for understanding potential competition with natural PD-1 ligands (PD-L1 and PD-L2) and predicting immunogenicity.

2. Mechanism of Action Studies

  • Cell-Based Functional Assays: The PD-1 pathway inhibits T-cell activation. In vitro assays using T-cells or Jurkat cells engineered to express PD-1 can assess nivolumab’s ability to block this pathway. Cytokine release assays measure IFN-γ and IL-2 levels as indicators of T-cell activation after nivolumab treatment.
  • Receptor Occupancy Assays: Flow cytometry is often used to assess nivolumab's binding to PD-1 on immune cells and the degree of receptor occupancy at different concentrations. This informs dosing and expected efficacy in vivo.

3. Antibody-Dependent Cellular Cytotoxicity (ADCC) and Complement-Dependent Cytotoxicity (CDC)

  • ADCC Assays: Although nivolumab's primary mechanism is immune checkpoint inhibition, ADCC and CDC assays test its potential to mediate cell killing via Fcγ receptors on immune effector cells or the complement cascade. For nivolumab, these are usually less relevant due to its IgG4 backbone, which minimizes effector functions to reduce off-target effects.

4. Pharmacokinetics and Stability Studies

  • FcRn Binding Assays: The neonatal Fc receptor (FcRn) plays a key role in extending mAb half-life by protecting it from lysosomal degradation. In vitro binding assays to FcRn, particularly at acidic pH, evaluate nivolumab’s likelihood of recycling and a prolonged half-life in circulation.
  • Thermal and Chemical Stability Testing: Differential scanning calorimetry (DSC) and other stability assays assess nivolumab's structural stability under various temperatures and pH conditions. These tests are essential for formulation development and ensuring stability during storage and administration.

5. Anti-Drug Antibody (ADA) Evaluation

  • ADA Assays: In vitro ADA assays predict the likelihood of immunogenic responses to nivolumab. These involve exposing immune cells to nivolumab and measuring the production of anti-drug antibodies using assays like bridging ELISAs or electrochemiluminescence assays.

6. Off-Target Binding and Toxicity

  • Cross-Reactivity Studies: These studies assess whether nivolumab binds non-specifically to other cell types or receptors, reducing potential adverse effects. Immunohistochemistry or flow cytometry methods can determine binding specificity across various tissue types.
  • Cytotoxicity Testing: Even though nivolumab is engineered to be non-cytotoxic, assays that monitor apoptosis or necrosis in non-target cells confirm its specificity and safety.

7. In Vitro-to-In Vivo Correlation (IVIVC)

  • PK/PD Modeling: In vitro data on nivolumab's binding kinetics, receptor occupancy, and cellular response guide the development of PK/PD models. These models predict how nivolumab behaves in vivo, helping to estimate dosing and efficacy in human trials.

Summary

In vitro studies for nivolumab focus on confirming PD-1 binding and inhibition, ensuring safety through reduced Fc effector function, and assessing stability and immunogenicity. These early-stage evaluations are crucial for determining dosing, mechanism of action, and potential adverse effects, ensuring that only well-characterized and promising candidates advance to clinical trials.

Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

Guideline on development and manufacture of lentiviral vectors (CHMP/BWP/2458/03)

The guideline with the reference number "CHMP/BWP/2458/03" pertains to the "Guideline on Development and Manufacture of Lentiviral Vectors." This guideline was developed by the Committee for Medicinal Products for Human Use (CHMP) and the Biotechnology Working Party (BWP) of the European Medicines Agency (EMA). It provides recommendations and regulatory guidance for the development and manufacture of lentiviral vectors, which are widely used in gene therapy and cell therapy applications. Here's an overview of the key points covered in this guideline: 1. Introduction: The guideline begins with an introduction highlighting the increasing importance of lentiviral vectors in advanced therapies and the need for guidance on their development and manufacture. 2. Scope: It defines the scope of the guideline, which covers the development and manufacture of lentiviral vectors intended for use in gene therapy and cell therapy products for human use. 3. Quality and Characte...
Read more

Stem-Loop PCR for siRNA

 Stem-loop PCR is a method often used for detecting and quantifying small RNAs, such as siRNA or miRNA, which are typically difficult to amplify directly due to their short lengths. The method involves the design of a stem-loop reverse transcription (RT) primer, which enhances specificity and stability of the short RNA during the RT-PCR process, allowing for sensitive detection and quantification of the siRNA. Here’s a detailed guide to how stem-loop PCR can be applied to siRNA detection: Key Steps in Stem-Loop PCR for siRNA Designing the Stem-Loop RT Primer : Structure : The stem-loop RT primer consists of a loop region flanked by complementary sequences on either side (the "stem"), which will fold back on itself to form a hairpin structure. Specific Binding Region : A short sequence complementary to the 3’ end of the siRNA is added at the end of the stem-loop primer to ensure specific binding to the siRNA target. Stabilization : The loop structure helps prevent primer-dimer...
Read more

FDA Guidance on Studying Multiple Versions of Cellular or Gene Therapy Products in Early-Phase Clinical Trials

 The purpose of this guidance is to offer advice to sponsors interested in conducting early-phase clinical trials for a single disease involving multiple variations of a cellular or gene therapy product. Sponsors aim to gather preliminary safety and efficacy data for these product variations within a single clinical trial. It's important to note that even though multiple product versions are studied together, each version is distinct and typically requires a separate investigational new drug application (IND) submission to the FDA. The primary goal of these early-phase clinical studies is to inform decisions about which product version(s) should be advanced for further development in later-phase trials. As such, these studies are not designed to provide the main evidence of effectiveness needed for a marketing application. They are generally not statistically powered to demonstrate a significant difference in efficacy between the different study arms. In this guidance, the FDA prov...
Read more

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below.  In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quanti...
Read more